HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

29 Jan 2024 22:53:49 By Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

10 Jan 2024 18:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

12 Dec 2023 22:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

12 Dec 2023 18:00:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

30 Nov 2023 18:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

08 Nov 2023 18:11:18 By Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

16 Oct 2023 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

29 Sep 2023 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

12 Sep 2023 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

11 Sep 2023 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

28 Aug 2023 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

20 Aug 2023 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

31 Jul 2023 06:41:53 By Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

19 Jul 2023 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Changes to Board of Directors and Technical Committee 

13 Jul 2023 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

09 Jul 2023 19:00:00 By Nasdaq GlobeNewswire

HUTCHMED to Announce 2023 Half-Year Financial Results

26 Jun 2023 03:30:00 By Nasdaq GlobeNewswire

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

15 Jun 2023 19:30:00 By Nasdaq GlobeNewswire

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

15 Jun 2023 09:30:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

09 Jun 2023 04:30:00 By Nasdaq GlobeNewswire